The Conversation (0)
Bloomberg reports that Amgen Inc will pay $10.5 billion to acquire Onyx Pharmaceuticals, giving Amgen access to a lucrative cancer drug.
Bloomberg reports that Amgen Inc (NASDAQ:AMGN) will pay $10.5 billion to acquire Onyx Pharmaceuticals (NASDAQ:ONXX), giving Amgen access to a lucrative cancer drug.
As quoted in the market news:
Amgen will pay $125 a share for Onyx’s outstanding stock, the companies said in a statement yesterday. Onyx’s Kyprolis, approved last year for a rare blood cancer, may spur more than $3 billion in revenue by 2021, according to analyst estimates compiled by Bloomberg. South San Francisco-based Onyx is now studying the medicine in an expanded group of patients.